Quick Answer
TANDEM DIABETES CARE INC reported Research And Development Expense of $92.05 million for the year ending 2021.
- TANDEM DIABETES CARE INC showed an increase of +44.8% in Research And Development Expense from 2020 to 2021.
- This data is from TANDEM DIABETES CARE INC's annual report (Form 10-K), filed with the SEC on February 22, 2022.
- XBRL data for this metric is available from 2012 to 2021 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2012 to 2021), TANDEM DIABETES CARE INC's Research And Development Expense has grown by 921.8%.
- Historical annual values: Fiscal year 2021: $92.05 million | Fiscal year 2020: $63.57 million | Fiscal year 2019: $45.20 million | Fiscal year 2018: $29.23 million | Fiscal year 2017: $20.66 million | Fiscal year 2016: $18.81 million | Fiscal year 2015: $16.96 million | Fiscal year 2014: $15.79 million | Fiscal year 2013: $11.08 million | Fiscal year 2012: $9.01 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: